DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain
摘要:
Four series of acridine-linked aniline mustards have been prepared and evaluated for in vitro cytotoxicity, in vivo antitumor activity, and DNA cross-linking ability. The anilines were attached to the DNA-intercalating acridine chromophores by link groups (-O-, -CH2-, -S-, and -SO2-) of widely varying electronic properties, providing four series of widely differing mustard reactivity where the alkyl chain linking the acridine and mustard moieties was varied from two to five carbons. Relationships were sought between chain length and biological properties. Within each series, increasing the chain length did not alter the reactivity of the alkylating moiety but did appear to position it differently on the DNA, since cross-linking ability (measured by agarose gel assay) altered with chain length, being maximal with the C4 analogue. The in vivo antitumor activities of the compounds depended to some extent on the reactivity of the mustard, with the least reactive SO2 compounds being inactive. However, DNA-targeting did appear to allow the use of less reactive mustards, since the S-linked acridine mustards showed significant activity whereas the parent S-mustard did not. Within each active series, the most active compound was the C4 homologue, suggesting some relationship between activity and extent of DNA alkylation.
VALU, KISIONE K.;GOURDIE, TRUDI A.;BORITZKI, THEODORE J.;GRAVATT, G. LANC+, J. MED. CHEM., 33,(1990) N1, C. 3014-3019
作者:VALU, KISIONE K.、GOURDIE, TRUDI A.、BORITZKI, THEODORE J.、GRAVATT, G. LANC+
DOI:——
日期:——
COMBINATION OF CD37 ANTIBODIES WITH CHLORAMBUCIL
申请人:Boehringer Ingelheim International GmbH
公开号:EP3008089A1
公开(公告)日:2016-04-20
US4150126A
申请人:——
公开号:US4150126A
公开(公告)日:1979-04-17
[EN] COMBINATION OF CD37 ANTIBODIES WITH CHLORAMBUCIL<br/>[FR] COMBINAISON D'ANTICORPS ANTI-CD37 ET DE CHLORAMBUCIL
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2014198330A1
公开(公告)日:2014-12-18
The present invention relates to immunotherapies that are based on depletion of CD37- positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/ patient using a combination of CD37 antibody /antibodies and chlorambucil. The combination of CD37 antibodies and chlorambucilis shown to have a synergistic effect. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity.
Everett et al., Journal of the Chemical Society, 1953, p. 2386,2387